ArticleCurrent microbiology2026
Antimicrobial Activity and Metabolic Profile of Bacteria from the Maros Pangkep Karst Region.
Article in Current microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Karst ecosystems are recognized as distinctive and extreme natural environments. Nevertheless, they continue to harbor a high degree of microbial diversity, including cave bacteria that can produce antimicrobial secondary metabolites. The rise in antibiotic-resistant cases, driven by the improper use of antibiotics, has created an urgent need to explore new antimicrobial compounds derived from natural sources. This study aimed to isolate soil bacteria from several caves in the Maros-Pangkep Karst Area. This study evaluated the identification of bacteria and their potential to inhibit pathogenic bacteria. Isolates were obtained from three different locations, including Leang Kassi, Leang Jarie, and Leang Ulu Wae. The results showed that the isolates from Leang Ulu Wae exhibited growth inhibition against Staphylococcus aureus and Escherichia coli in agar diffusion assays. The characterization of metabolite compounds was performed using Fourier-transform infrared (FTIR) spectroscopy and gas chromatography-mass spectrometry (GC-MS) analysis, which tentatively revealed several putative secondary metabolites. However, owing to the absence of procedural blanks (solvent-only and uninoculated medium controls), these tentative compound assignments should be interpreted cautiously, as potential laboratory- or media-derived contaminants cannot be fully excluded. Additionally, molecular identification using 16S rRNA indicated that the bacteria in the Leang Ulu Wae isolate belonged to the genus Exiguobacterium. This finding highlights the potential of cave bacteria as a source of novel bioactive compounds. These compounds can be used to develop novel antimicrobial agents.
Indexed as
Identifiers
41910777What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.